Swami Murugappan

Swami Murugappan is an executive consultant serving the role of Chief Medical Officer at Tizona Therapeutics. He will be responsible for developing and executing clinical development strategies for the Tizona Therapeutics pipeline. He is the founder and owner of Trident Bio Consulting Inc, which provides clinical development services to life sciences organizations focused on Hematology and Oncology drug development. Previously, he was the Vice President at Nutcracker Therapeutics, a mRNA platform company, where he led both non-clinical and clinical functions and was responsible for driving programs from preclinical to IND, execution of clinical studies, and managing regulatory filing activities. Prior to Nutcracker, Swami was the Executive Director and global product lead for a CD19 CAR-T (Tecartus™) at Kite Pharma, where he led a successful U.S. and EU filing and subsequent FDA approval of Tecartus™ for relapsed and refractory mantle cell lymphoma. Before Kite, Swami worked at Amgen in early and late phase oncology programs within clinical development and supported global filings and approvals of Vectibix™ and ImLygic™ (first in class Oncolytic virus).

Swami is a ABIM board-certified Hematologist and Oncologist. He completed his fellowship training at the University of Washington/Fred Hutchinson Cancer Research Center after his Internal Medicine training at Drexel University. He graduated from Temple University with his PhD in Physiology and received his MD degree from Chennai Medical College, India.